Plasma Bags Research Articles

Plasma Photoinactivation of Bacterial Isolated from Blood Donors Skin: Potential of Security Barrier in Transfusional Therapy.

The presence of skin bacteria capable of forming biofilm, exhibiting antibiotic resistance, and displaying virulence represents a significant challenge in the field of transfusion medicine. This underscores the necessity of enhancing the microbiological safety of blood and blood components against pathogens with virulent characteristics. The aim of this work was to demonstrate bacterial inactivation in plasma by using a photoinactivation method against virulent bacteria and to evaluate coagulation factors before and after treatment. Logarithmic loads of biofilm-producing, antibiotic-resistant, and virulent bacteria isolated from skin (Enterobacter cloacae, Klebsiella ozaenae, and Staphylococcus epidermidis) were used in artificial contamination assays of fresh frozen plasma bags and subjected to photoreduction. FVIII and FI activity were evaluated before and after photoinactivation. The photoinactivation of plasma was demonstrated to be an effective method for the elimination of these bacteria. However, the efficiency of this method was found to be dependent on the bacterial load and the type of test microorganism. Conversely, decay of coagulation factors was observed with net residual activities of 61 and 69% for FVIII and FI, respectively. The photoinactivation system could have a bias in its effectiveness that is dependent on the test pathogen. These findings highlight the importance of employing technologies that increase the safety of the recipient of blood and/or blood components, especially against virulent bacteria, and show the relevance of the role of photoinactivation systems as an option in transfusion practice.

Design and Experimentation of a Residual-Input Tube-End Cutting System for Plasma Bags Based on Machine Vision

In response to the lack of plasma bag-breaking equipment and time-consuming manual recovery of plasma in China, this study focuses on the distal end cutting of a plasma bag residual-input tube and designs a machine-vision-based plasma bag residual-input tube cutting system. The system comprises a plasma bag rotation device, a bottom disc, an image acquisition device, a cutting device, and a device control system. The image acquisition device captures images of the rotating plasma bag and calculates the Euclidean distance from the end of the plasma bag input-tube distal end to the outer edge of the bottom support plate and the distance from the input-tube distal end to the centerline of the plasma bag. Two distinct value acquisition algorithms are designed for the two types of input tubes. The screw slide moves accordingly. When the plasma bag is above the cutting part, the cutting part cuts the end of the residual-input tube of the plasma bag. The prototype performance tests reveal that the cutting error is within 10% of the end of the plasma bag input tube distal end, the cutting success rate is 100%, and the processing time for each bag is 2.5 s, which meets the time requirements of the plasma bag breaker.

The effects of leukoreduction on canine blood unit weight and processing time.

Despite a lack of strong evidence of benefit, leukoreduction is employed to decrease the risk of leukocyte-induced transfusion reactions. However, the impact of leukoreduction on blood bank costs and inventory management is not well understood. The purpose of this study was to determine whether leukoreduction of whole blood increases total processing time and weight loss from packed red blood cells (PRBCs) and plasma relative to bags created from nonleukoreduced whole blood. A total of 68 canine whole blood collections were divided equally into leukoreduced and nonleukoreduced groups (N=34 in each). There was no significant difference between groups in mean PRBC or plasma unit weights or processing times. Leukoreduced PRBC bags lost a significantly greater proportion of weight during processing than did nonleukoreduced PRBC bags (P<0.01), which is attributed to red and white blood cells lost in the filtration process. Leukoreduction did not lead to a significant increase in processing times or smaller PRBCs or plasma bags compared to nonleukoreduced bags. The blood remaining in the leukoreduction filter following filtration is primarily composed of red blood cells, with minimal plasma retained.

Impact of the pathogen inactivation process on the migration of di(2-ethylhexyl) phthalate from plasma bags.

Di(2-ethylhexyl) phthalate (DEHP) is a toxic plasticizer that is commonly used in the manufacture of polyvinyl chloride (PVC) blood bags. It is well known that DEHP can migrate from a medical device into the blood plasma. For safety reasons, pathogens in plasma must be inactivated; however, this process may increase DEHP migration. Here, we assessed the impact of illumination-based pathogen inactivation on the migration of DEHP from PVC bags into plasma. Pairs of native PVC-DEHP plasma bags were pooled. Each pool was then split into a pathogen-inactivated bag and a control bag. After illumination, the plasma concentrations of DEHP and its main metabolite (mono(2-ethylhexyl) phthalate, MEHP) in each bag were assayed and compared using liquid chromatography-tandem mass spectrometry. Concentrations were evaluated in repeated-measures, two-way analyses of variance. The MEHP concentration was significantly associated with storage but not with illumination (p= 0.0001). The DEHP concentration stayed constant throughout the storage period. The DEHP equivalent concentration (corresponding to the overall plasticizer migration rate into plasma) was not significantly associated with illumination (p= 0.3) or storage (p= 0.09; mean ± standard deviation of the mean DEHP concentration for all conditions: 147.9± 11.3μg/ml). Illumination-based inactivation of pathogens in plasma did not increase the DEHP equivalent concentration, relative to control (non-inactivated) plasma.

Surrogate test performance for SARS-CoV-2 neutralizing antibodies (nAbs) for convalescent plasma (CCP): How useful could they be?

BackgroundCOVID‐19 high‐titer CCP selection is a concern, because neutralizing antibody (nAb) testing requires sophisticated labs and methods. Surrogate tests are an alternative for measuring nAb levels in plasma bags, including those that are pathogen‐reduced.Study design/methodsWe studied a panel consisting of 191 samples from convalescent donors tested by nAb (CPE‐VNT), obtained from 180 CCP donations (collection: March 20–January 21) and 11 negative controls, with a total of 80 and 111 serum and plasma samples (71 amotosalen/UV treated), with nAb titers ranging from negative to 10,240. Samples were blindly tested for several surrogates: one anti‐RBD, two anti‐spike, and four anti‐nucleocapsid tests, either isolated or combined to improve their positive predictive values as predictors of the presence of high‐titer nAbs, defined as those with titers ≥160.ResultsExcept for combined and anti‐IgA/M tests, all isolated surrogate tests showed excellent performance for nAb detection: sensitivity (98.3%–100%), specificity (85.7%–100%), PPV (98.9%–100%), NPV (81.3%–100%), and AUC (0.93–0.96), with a variable decrease in sensitivity and considerably lower specificity when using FDA authorization and concomitant nAb titers ≥160. All surrogates had AUCs that were statistically different from CPE‐VNT if nAb≥160, including when using combined, orthogonal approaches.ConclusionsSurrogate tests (isolated or in combination) have an indirect good performance in detecting the presence of nAb, with lower sensitivity and specificity when high nAb titer samples are used, possibly accepting a considerable number of donors whose nAb titers are actually low, which should be evaluated by each laboratory responsible for CCP collection.

Screening for parvovirus B19 antigen through chemiluminescent enzyme immunoassay is equivalent to B19 nucleic acid amplification test-based screening of pooled plasma.

Human parvovirus B19 (B19) is a pathogen that threatens the quality of plasma products. Therefore, health authorities have mandated measures against B19 contamination of plasma pools. The US FDA has recommended a B19 genome level of 104 IU/ml or lower in pooled plasma lots. Therefore, the B19 nucleic acid amplification test (B19-NAT) has been introduced in many plasma fractionators. However, in the Japanese Red Cross, which is the only approved blood collector in Japan, the B19 antigen test has been introduced for screening donated blood in Japan. Therefore, to clarify whether the antigen test is robust enough to screen blood samples according to the FDA recommendation, we evaluated B19 genome levels in each pooled plasma lot from 2003 to 2020. Data of 5576 pooled plasma lots from factories A and B, which were derived from plasma bags and passed the B19 antigen-based tests, receptor-mediated hemagglutination assay (B19-RHA), or chemiluminescent enzyme immunoassay (B19-CLEIA), during 2003 to 2020, were evaluated. The amount of B19 genome in each lot was determined using quantitative or semiquantitative B19-NAT. The B19 genome levels in pooled plasma lots screened using B19-RHA did not meet the FDA recommendation, whereas the lots derived from B19-CLEIA fulfilled the FDA recommendation, even during the B19 epidemic in Japan. The results suggest that the B19-CLEIA donor screening for plasma pools is also useful in light of the US FDA recommendation.

Purification of canine albumin by heat denaturation in a plasma bag.

To design and evaluate a method to purify canine albumin from fresh frozen plasma (FFP) or stored plasma (SP) in a manner that could be applied clinically. In vitro experimental study. FDA licensed Blood Bank Laboratory and University biochemistry laboratory. None. Using equipment that is typically found in veterinary blood banks, plasma bags were thawed, injected with the heat stabilizing agent, sodium caprylate, and then heated and acidified to denature all but albumin proteins. Albumin-rich supernatant was removed, the pH was neutralized, and then pasteurized and refrigerated. Albumin and total plasma protein concentrations were measured and the product was cultured for bacteria at 0, 7, 14, 30, and 60 days post-processing. Seventeen bags of plasma were analyzed for purity, yield, and sterility of the finished albumin product. Bags were divided into categories based on the age of the frozen plasma. Mean yield of albumin for all bags was 77.3% and mean purity was 91.2%. There was no difference between old stored plasma, new stored plasma, and FFP with regard to yield (P=0.31) or purity (P=0.24) based on one-way analysis of variances. Overall 1 of 17 bags of plasma (5.9%) tested positive for bacterial contamination on day 60 after processing. Sodium caprylate is able to stabilize canine albumin enabling it to withstand heating that denatures other plasma proteins. The resulting albumin product is of sufficient quality to potentially be used therapeutically as a colloidal resuscitative fluid. Further study is needed into its safety and effect in dogs.

Hepatitis E virus in donor plasma collected in Japan.

Human hepatitis E virus (HEV) is prevalent worldwide. Iatrogenic HEV has recently been identified based on the reports of transfusion-transmitted cases. The detection rate of HEV-RNA and seroprevalence of HEV-IgG/IgM have been regionally evaluated in Japan, and donor plasma collected in Hokkaido is currently screened by nucleic acid amplification testing. However, the detection rate of HEV-RNA in blood donors in Japan outside of Hokkaido has not been reported. A total of 620 140 qualified donor plasma samples from Japanese regions excluding Hokkaido were tested for HEV-RNA (pools of 50 or 500) between 2004 and 2014. HEV-RNA-positive plasma bags were identified, and the HEV viral load, genotype and anti-HEV immunoglobulin (Ig)G/IgM were evaluated. The detection rate of HEV-RNA (pools of 50) was 1/15 075 and higher in eastern than in western Japan. All 36 HEV-RNA-positive samples were genotype 3 with viral load ranging from <1·69 to 7·22 log10 copies/ml. Our detection rate of HEV-RNA in donor populations in Japan outside Hokkaido (1/15 075 donations) is generally lower than reported in Europe and lower than previously reported for Hokkaido (1/8173 donations). As methods varied, we cannot exclude that these differences are reflective of differing RNA detection limits. In contrast to Hokkaido where genotype 4 has been reported among blood donations, all our positive donations were genotype 3, which is less pathogenic.

Gilbert's syndrome in healthy blood donors what next??

Settings:This study was done in a tertiary care hospital having bed strength of more than 700 beds at SDM Medical College of Medical Sciences and Hospital, Dharwad, located in Northern Karnataka.Aim:The study was done to ascertain prevalence of Gilbert's syndrome in healthy blood donors and review the literature about feasibility of utilizing blood components from Gilbert's syndrome donors.Materials and Methods:The study was done for 18 months and 7030 whole blood units were collected and all the units were subjected to mandatory transfusion-transmitted screening and all the plasma bags which were icteric on visual inspection were subjected to hematological and biochemical investigations to rule out other causes of hyperbilirubinemia.Results:Seven thousand and thirty units were collected and 445 (6.3%) were discarded due to various reasons. Of them, 50 units (0.71%) had Gilbert's syndrome. All had unconjugated hyperbilirubinemia and other hematological and liver function tests were within normal range. Statistical analysis was done to find mean, median, and standard deviation from mean and standard error of mean with lower and upper confidence limits.Conclusion:Majority of blood donors whose plasma is icteric are suffering from Gilbert's syndrome (GS). This disease does not cause any harm to donor or patient but raises a lot of concern as many severe disorders also manifest in similar way. The available literature shows that all blood components can be used from donors suffering from GS. There should be introspection. Proper guidelines are to be framed about the use and discarding of blood components in donors with GS.

Commercially available blood storage containers

Plastic blood bags improve the safety and effectiveness of blood component separation and storage. Progress towards optimal storage systems is driven by medical, scientific, business and environmental concerns and is limited by available materials, consumer acceptance and manufacturing and regulatory concerns. Blood bag manufacturers were invited to submit lists of the bags they manufacture. The lists were combined and sorted by planned use. The lists were analysed by experts to assess the degree to which the products attend to scientific problems. Specific issues addressed included the use of di-ethylhexyl phthalate (DEHP) as plasticizer for polyvinyl chloride (PVC) blood bags, the size, material and thickness of platelet bags, and the fracture resistance of plasma bags. Alternatives to DEHP for red blood cell (RBC) storage exist, but are mostly in a developmental stage. Plastic bags (DEHP-free, PVC-free) for platelet storage with better gas diffusion capabilities are widely available. Alternatives for plasma storage with better fracture resistance at low temperatures exist. Most RBC products are stored in DEHP-plasticized PVC as no fully satisfactory alternative exists that ensures adequate storage with low haemolysis. A variety of alternative platelet storage systems are available, but their significance - other than improved oxygen transport - is poorly understood. The necessity to remove DEHP from blood bags still needs to be determined.

Pathogen reduction in human plasma treated with Riboflavin and UV light: impact on coagulation factor VIII

Background: Pathogen reduction system is expected to effectively reduce pathogen load of blood components while simultaneously maintaining the quality of cells and proteins. Pathogen reduction in human plasma treated with a combination of riboflavin (vitamin B2) and UV light is based on irreversible, oxydative damage of nucleic acids. In this way it prevents further replication of viruses, bacteria and parasites eventually present in the plasma. The aim of our study was to evaluate the influence of photo-inactivation process on the coagulation factor VIII (FVIII) present in plasma. Methods: We have tested 30 units of fresh frozen plasma (FFP), obtained by processing single donor whole blood. We have pooled two units of fresh plasma, identical ABO blood groups, and by dividing them got 15 pairs of fresh frozen plasma (30 units). One pair included a test unit, which will be photo-inactivated (FP) and a control unit (KP). We added 35 ml of riboflavin (500 µM) in the treated unit (FP) and illuminated it with UV lihgt (6.24 J/ml) on the Mirasol Illuminator (Caridian BCT Biotechnologies; USA). In order to obtain equal dilution, we added 35 ml of saline into the control unit. After illumination, we took samples (1.5 ml aliquots) from FP and KP and froze them at -80 °C. Control and treated plasma bags were frozen simultaneously at -30 °C. After one month, samples were thawed and concentration of F VIII in FP and KP units were compared. Results: Median value FVIII in the treated plasma was 0.84 IE/ml (0.59–0.92 IE/ml). Median percent recovery was 68 % (59–78 %). Average inactivation time was 3 minutes and 9 seconds ± 22 seconds . Conclusion: The study results showed that the pathogen reduction process using Mirasol technology affects the concentration of F VIII in plasma. FVIII concentration in the treated units is consistent with the recommendations and is comparable to the concentration of FVIII after treatment with other inactivation methods.

Clotting factor activity in thawed Octaplas® LG during storage at 2–6 °C for 6 days from a quality assurance point of view

IntroductionOctaplas® LG is a second-generation solvent/detergent-treated plasma that offers an additional safety benefit by prion elimination. The stability of clotting factors of the new S/D plasma after thawing has not been investigated yet. This study intended to measure the time course of fibrinogen, FII, FV, FVII, FVIII, FIX, PC, fPS and PI through storage at 2–6°C over 6days. Materials and methodsWe investigated 20 plasma bags (five bags per blood group) and measured fibrinogen, FII, FV, FVII, FVIII, FIX, PC, fPS and PI immediately after thawing and after 2, 4, 6, 24, 48, 72, 96, 120 and 144h storage at 2–6°C. Five separate plasma bags were thawed and stored at 2–6°C for microbiological assessment. After 6days samples were drawn for blood cultures that were incubated for six more days. ResultsAfter 6days FII, FIX and PC showed no significant changes. FV (−16%, p<0.001), FVII (−19%, p<0.001), FVIII (−19%, p<0.001), FXI (−13%, p<0.0001) and fPS (−4%, p<0.0007) decreased significantly. PI levels were stable at 56%. The microbiological investigation showed no bacterial contamination. ConclusionsIn Octaplas® LG plasma clotting factors decreased slightly through storage of 6days. PI levels were remarkably higher and stable over time in the new Octaplas® LG. Stability of stored Octaplas® LG was limited by the decrease of FVIII to 53%, which may warrant storage up to 24h from a quality assurance point of view. This could result in reduced plasma wastage and costs for healthcare givers.

Quark gluon bags as reggeons

The influence of the medium-dependent finite width of quark gluon plasma (QGP) bags on their equation of state is analyzed within an exactly solvable model. It is argued that the large width of the QGP bags not only explains the observed deficit in the number of hadronic resonances but also clarifies the reason why the heavy QGP bags cannot be directly observed as metastable states in a hadronic phase. The model allows us to estimate the minimal value of the width of QGP bags being heavier than 2 GeV from a variety of the lattice QCD data and get that the minimal resonance width at zero temperature is about 600 MeV, whereas the minimal resonance width at the Hagedorn temperature is about 2000 MeV. As shown, these estimates are almost insensitive to the number of the elementary degrees of freedom. The recent lattice QCD data are analyzed and it is found that in addition to the {sigma}T{sup 4} term the lattice QCD pressure contains T-linear and T{sup 4}lnT terms in the range of temperatures between 240 and 420 MeV. The presence of the last term in the pressure bears almost no effect on the width estimates. Our analysis shows thatmore » at high temperatures the average mass and width of the QGP bags behave in accordance with the upper bound of the Regge trajectory asymptotics (the linear asymptotics), whereas at low temperatures they obey the lower bound of the Regge trajectory asymptotics (the square root one). Since the model explicitly contains the Hagedorn mass spectrum, it allows us to remove an existing contradiction between the finite number of hadronic Regge families and the Hagedorn idea of the exponentially growing mass spectrum of hadronic bags.« less

Fresh-frozen plasma, pathogen-reduced single-donor plasma or bio-pharmaceutical plasma?

Three types of therapeutic plasma are available that differ in their manufacturing processes, composition, clinical efficacy, and side effects. Quarantine-stored, not pathogen-reduced fresh-frozen plasma (QFFP) is prepared from single whole blood or plasma donations. The manufacture of pathogen-reduced single-donor plasmas such as methylene blue-light treated (MLP) or amotosalen-ultraviolet light treated plasma (ALP) involves the addition of a chemical followed by irradiation and subsequent removal of the chemical. Both plasma types show substantial fluctuation of clotting factor and inhibitor levels according to interindividual variations, and both carry the risk of inducing transfusion-associated lung injury (TRALI). Photo-oxidation in pathogen-reduced single-donor plasmas reduces clottable fibrinogen and other clotting factors markedly, and there is a lack of clear evidence showing whether this is harmful or not. MLP also appears to be less effective clinically than QFFP. Like clotting factor or inhibitor concentrates, solvent/detergent-treated plasmas (SDP) are bio-pharmaceutical preparations derived from large plasma pools, and variations in plasma protein levels from batch-to-batch are for that reason low. The SD manufacturing process inevitably involves a considerable reduction of plasmin inhibitor (PI), and moderate reduction of all other clotting factors and inhibitors in the final plasma bags. Clinical studies and broad clinical use have however shown that this does not significantly reduce clinical efficacy or increase adverse events. SDPs obviously do not induce TRALI and the risk of allergic reactions is significantly lower than for QFFP. Common to all three plasma types is that the time between donation and freezing the plasma, and whether plasma from whole blood or apheresis plasma is used as starting material, are decisive determinants for the clotting factor and inhibitor potencies in the final bags. Plasma frozen 3–6 h after donation, and apheresis plasma, contain markedly greater amounts of clotting factors and inhibitors than plasma frozen 15–24 h after collection or plasma from whole blood. Lyophilisation and the pooling of single-donor plasma units with ABO blood group in suitable proportions (Uniplas ™) facilitate SDP handling and logistics without loss of clinical efficacy. SDP is obviously at least as cost-effective as QFFP if non-infectious adverse events including TRALI are taken into account, at least in younger patients and patients with good prognosis.

Reply to: [Comment to: Recombinant erythropoietin found in seized blood bags from sportsmen. Haematologica 2008;93:313-4

We appreciate the comments from Lippi et al. on our previous letter[1][1] addressing the detection of rHuEPO in seized plasma bags and its potential further usefulness. We are pleased to forward some relevant clarifications. The availability of blood (plasma or serum) as a biological matrix for

Thawing Procedures and the Time Course of Clotting Factor Activity in Fresh-Frozen Plasma: A Controlled Laboratory Investigation

In this study, we evaluated the effects of the thawing process of 2 commercially available devices on the activity of clotting factors, inhibitors and activation markers of the hemostatic system in fresh-frozen plasma (FFP). In an experimental procedure, FFP was thawed under running warm water at 42 degrees C. Plasma of 20 healthy donors was sampled, separated, and distributed in 3 plasma bags. Within 2 h after sampling plasma bags was frozen at a temperature of -30 degrees C to -40 degrees C and stored for at least 8 wk. After sampling (baseline) as well as immediately and 1, 2, 4, and 6 h after thawing, the activity of FV, FVII, FVIII, fibrinogen, fibrin monomers (FM), d-dimers (DD), alpha2-antiplasmin (alpha2-AP), and protein S (PS) was determined from each plasma bag. From 1 h to 6 h after thawing, no significant differences in the activity of the investigated coagulation markers dependent on the thawing procedure were found. However, immediately after thawing and independent of the thawing procedure, the activity of FVII was significantly decreased (P < 0.01), whereas FM were significantly increased (P = 0.001). The thawing procedures studied exhibited no significant influence on activity and stability of the investigated markers of coagulation over the study period. The decreased activity of FVII and the clinical significance of the increase in FM require further research.

Determination of phosphoric acid triesters in human plasma using solid-phase microextraction and gas chromatography coupled to inductively coupled plasma mass spectrometry

A simple and sensitive method for determination of phosphoric acid triesters at trace levels in human plasma sample is described. In this work, solid-phase microextraction (SPME) is employed as a sample preparation procedure for extraction and pre-concentration of alkyl and aryl phosphates followed by gas chromatography coupled to inductively coupled plasma mass spectrometry (GC–ICP-MS) for phosphorus-specific and very sensitive determination of these compounds in human plasma. The detection limits from blood plasma were 50 ng L −1 (tripropyl phosphate), 17 ng L −1 (tributyl phosphate), 240 ng L −1 (tris(2-chloroethyl) phosphate) and 24 ng L −1 (triphenyl phosphate). Sample preparation involves plasma deproteinization followed by direct immersion SPME with 65 μm poly(dimethylsiloxane/divinylbenzene) fiber. Extraction was performed at 40 °C for 30 min and at pH 7.0 in 10 mM sodium carbonate buffer. The reported method, to our knowledge, describes the first application of SPME with element-specific detection for analysis of phosphoric acid esters. Application of the method to the plasma samples, previously stored in poly(vinyl chloride) plasma bags revealed the presence of triphenyl phosphate, which was further confirmed by SPME GC time-of-flight high-resolution mass spectrometry.

Molecular evidence of tumour cell removal from salvaged blood after irradiation and leucocyte depletion.

Intra-operative autologous blood recovery offers many advantages. However, blood salvage during cancer surgery is of limited use due to the potential presence of circulating tumour cells. It was the aim of this study to show that intra-operative salvage blood can be freed of cells and cellular DNA after leucoreduction by filtration and irradiation of washed blood. Known amounts of tissue culture derived from carcinoma, melanoma and osteosarcoma were added to whole blood bags. This mixture was then submitted to washing, leucoreduction and irradiation. Samples were studied stepwise in relation to the integrity and size of DNA by the polymerase chain reaction (PCR). After filtration and irradiation, PCR targeting the beta-globin gene (268 bp amplicon) was negative. Our results were corroborated by studying plasma samples added with tumoural cells. Using PCR methodology, we showed the absence of DNA from cells in experimentally contaminated blood and plasma bags after filtration and irradiation. This experimental study is an effort to ensure the safety of intra-operative autologous transfusion.

Hepatitis G Virus Infection in Screened Chinese Blood Donors

To determine the prevalence of the recently identified hepatitis G virus (HGV)/GBV-C in screened Chinese paid blood donors. Two hundred and seventy-nine plasma samples were tested for HGV RNA by RT-PCR with nested primers from the 5'-noncoding region of GBV-C. All samples were obtained from plasma or blood bags that had been screened twice by routine selection tests (ALT, HBsAg, Anti-HCV, anti-HIV, and syphilis) and were available for clinical use. HGV RNA was detected in 2 (4%) of 50 paid plasma donors from the Beijing Red Cross Blood Center, 1 (2%) of 50 paid blood donors from Taiyuan, and 9 (5%) of 179 paid blood donors from Hebei, a total HGV detection rate of 4.3% (12/279). Our data suggest that HGV infection is relatively frequent even in screened donors, at least in paid screened donors, although larger-scale studies are required.

Hepatitis G Virus Infection in Screened Chinese Blood Donors

Background and Objectives: To determine the prevalence of the recently identified hepatitis G virus (HGV)/GBV-C in screened Chinese paid blood donors. Materials and Methods: Two hundred and seventy-nine plasma samples were tested for HGV RNA by RT-PCR with nested primers from the 5′-noncoding region of GBV-C. All samples were obtained from plasma or blood bags that had been screened twice by routine selection tests (ALT, HBsAg, Anti-HCV, anti-HIV, and syphilis) and were available for clinical use. Results: HGV RNA was detected in 2 (4%) of 50 paid plasma donors from the Beijing Red Cross Blood Center, 1 (2%) of 50 paid blood donors from Taiyuan, and 9 (5%) of 179 paid blood donors from Hebei, a total HGV detection rate of 4.3% (12/279). Conclusions: Our data suggest that HGV infection is relatively frequent even in screened donors, at least in paid screened donors, although larger-scale studies are required.